Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle

Launched by ASTRAZENECA · Oct 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to improve care for patients with Chronic Obstructive Pulmonary Disease (COPD) after they experience flare-ups, known as exacerbations. The research involves working with 36 hospitals to see if a specific care plan, called a "transition bundle," can help patients recover better and avoid future hospital visits. The trial will include about 1,368 patients aged between 40 and 80 who have been diagnosed with COPD and have had at least two moderate flare-ups or one severe flare-up in the past year.

To be eligible for the trial, participants should have a confirmed diagnosis of COPD and be able to provide consent to join. Importantly, those who have been on a specific type of inhaler treatment for a long time, or have stable COPD symptoms, may not qualify. If you choose to participate, you can expect to receive care that aligns with the new approach being tested, which aims to help improve your overall health and manage your COPD more effectively. This trial is currently recruiting participants and welcomes all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed COPD (post- bronchodilator FEV1/FVC \< 0.7)
• • 40\~80 years
• • CAT≥10
• • At least two moderate or at least one severe exacerbation history in past 1 year
• • Able to sign informed consent
• Exclusion Criteria:
• • Continuous triple inhalation therapy for ≥6 months at baseline (include single inhaler and multiple inhalers)
• • Stable COPD (symptom such as cough, sputum and shortness of breath are mild or stable, clinical condition has basically returned to pre-exacerbation)
• • Comorbidities require/contraindicate long-term use of glucocorticoid treatment: asthma, interstitial lung disease, sarcoidosis, cystic fibrosis, active tuberculosis recurrent aspiration pneumonia ect.
• • Serious comorbidities threaten to life expected survival time no more than 1 year: severe heart disease, severe chronic liver, severe kidney disease, cerebrovascular disease with long-term bed rest and malignant tumours ect.
• • Not living in the healthcare area
• • Patients currently participating in any other interventional studies